These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

571 related articles for article (PubMed ID: 25512523)

  • 1. Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma.
    Perry JA; Kiezun A; Tonzi P; Van Allen EM; Carter SL; Baca SC; Cowley GS; Bhatt AS; Rheinbay E; Pedamallu CS; Helman E; Taylor-Weiner A; McKenna A; DeLuca DS; Lawrence MS; Ambrogio L; Sougnez C; Sivachenko A; Walensky LD; Wagle N; Mora J; de Torres C; Lavarino C; Dos Santos Aguiar S; Yunes JA; Brandalise SR; Mercado-Celis GE; Melendez-Zajgla J; Cárdenas-Cardós R; Velasco-Hidalgo L; Roberts CW; Garraway LA; Rodriguez-Galindo C; Gabriel SB; Lander ES; Golub TR; Orkin SH; Getz G; Janeway KA
    Proc Natl Acad Sci U S A; 2014 Dec; 111(51):E5564-73. PubMed ID: 25512523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. P53 suppresses cell proliferation, metastasis, and angiogenesis of osteosarcoma through inhibition of the PI3K/AKT/mTOR pathway.
    Song R; Tian K; Wang W; Wang L
    Int J Surg; 2015 Aug; 20():80-7. PubMed ID: 25936826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of X-Box Binding Protein 1 (XBP1) Correlates to Poor Prognosis and Up-Regulation of PI3K/mTOR in Human Osteosarcoma.
    Yang J; Cheng D; Zhou S; Zhu B; Hu T; Yang Q
    Int J Mol Sci; 2015 Dec; 16(12):28635-46. PubMed ID: 26633383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. mTOR signaling in osteosarcoma: Oncogenesis and therapeutic aspects (Review).
    Hu K; Dai HB; Qiu ZL
    Oncol Rep; 2016 Sep; 36(3):1219-25. PubMed ID: 27430283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Inhibitory effect and significance of rapamycin on the mammalian target of rapamycin signaling pathway in osteosarcoma stem cells and osteosarcoma cells].
    Liu PY; Zhang WB; Wang J; Shen YH; Wei YY
    Zhonghua Zhong Liu Za Zhi; 2013 Mar; 35(3):175-80. PubMed ID: 23879996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nuclear receptor modulators inhibit osteosarcoma cell proliferation and tumour growth by regulating the mTOR signaling pathway.
    Yuan B; Shi K; Zha J; Cai Y; Gu Y; Huang K; Yue W; Zhai Q; Ding N; Ren W; He W; Xu Y; Wang T
    Cell Death Dis; 2023 Jan; 14(1):51. PubMed ID: 36681687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NVP-BEZ235, a dual PI3K/mTOR inhibitor, inhibits osteosarcoma cell proliferation and tumor development in vivo with an improved survival rate.
    Gobin B; Battaglia S; Lanel R; Chesneau J; Amiaud J; Rédini F; Ory B; Heymann D
    Cancer Lett; 2014 Mar; 344(2):291-8. PubMed ID: 24333720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic Screening Identifies Dual PI3K and mTOR Inhibition as a Conserved Therapeutic Vulnerability in Osteosarcoma.
    Gupte A; Baker EK; Wan SS; Stewart E; Loh A; Shelat AA; Gould CM; Chalk AM; Taylor S; Lackovic K; Karlström Å; Mutsaers AJ; Desai J; Madhamshettiwar PB; Zannettino AC; Burns C; Huang DC; Dyer MA; Simpson KJ; Walkley CR
    Clin Cancer Res; 2015 Jul; 21(14):3216-29. PubMed ID: 25862761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting osteosarcoma.
    Reed DE; Shokat KM
    Proc Natl Acad Sci U S A; 2014 Dec; 111(51):18100-1. PubMed ID: 25512494
    [No Abstract]   [Full Text] [Related]  

  • 10. mTOR: An attractive therapeutic target for osteosarcoma?
    Ding L; Congwei L; Bei Q; Tao Y; Ruiguo W; Heze Y; Bo D; Zhihong L
    Oncotarget; 2016 Aug; 7(31):50805-50813. PubMed ID: 27177330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular Mechanisms and microRNAs in Osteosarcoma Pathogenesis.
    Kushlinskii NE; Fridman MV; Braga EA
    Biochemistry (Mosc); 2016 Apr; 81(4):315-28. PubMed ID: 27293089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of mTOR signaling by oleanolic acid contributes to its anti-tumor activity in osteosarcoma cells.
    Zhou R; Zhang Z; Zhao L; Jia C; Xu S; Mai Q; Lu M; Huang M; Wang L; Wang X; Jin D; Bai X
    J Orthop Res; 2011 Jun; 29(6):846-52. PubMed ID: 21246613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aplasia Ras homologue member Ⅰ overexpression inhibits tumor growth and induces apoptosis through inhibition of PI3K/Akt survival pathways in human osteosarcoma MG-63 cells in culture.
    Ye K; Wang S; Yang Y; Kang X; Wang J; Han H
    Int J Mol Med; 2015 Sep; 36(3):776-82. PubMed ID: 26165148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blockade of epidermal growth factor receptor/mammalian target of rapamycin pathway by Icariside II results in reduced cell proliferation of osteosarcoma cells.
    Geng YD; Yang L; Zhang C; Kong LY
    Food Chem Toxicol; 2014 Nov; 73():7-16. PubMed ID: 25119583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RASSF5 inhibits growth and invasion and induces apoptosis in osteosarcoma cells through activation of MST1/LATS1 signaling.
    Zhou XH; Yang CQ; Zhang CL; Gao Y; Yuan HB; Wang C
    Oncol Rep; 2014 Oct; 32(4):1505-12. PubMed ID: 25109282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
    Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
    BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR-218 inhibits the invasion and migration of colon cancer cells by targeting the PI3K/Akt/mTOR signaling pathway.
    Zhang X; Shi H; Tang H; Fang Z; Wang J; Cui S
    Int J Mol Med; 2015 May; 35(5):1301-8. PubMed ID: 25760926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Caffeine induces apoptosis of osteosarcoma cells by inhibiting AKT/mTOR/S6K, NF-κB and MAPK pathways.
    Miwa S; Sugimoto N; Yamamoto N; Shirai T; Nishida H; Hayashi K; Kimura H; Takeuchi A; Igarashi K; Yachie A; Tsuchiya H
    Anticancer Res; 2012 Sep; 32(9):3643-9. PubMed ID: 22993301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-throughput genotyping in osteosarcoma identifies multiple mutations in phosphoinositide-3-kinase and other oncogenes.
    Choy E; Hornicek F; MacConaill L; Harmon D; Tariq Z; Garraway L; Duan Z
    Cancer; 2012 Jun; 118(11):2905-14. PubMed ID: 22006429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PDGFRβ modulates aerobic glycolysis in osteosarcoma HOS cells via the PI3K/AKT/mTOR/c-Myc pathway.
    Tang HY; Guo JQ; Sang BT; Cheng JN; Wu XM
    Biochem Cell Biol; 2022 Feb; 100(1):75-84. PubMed ID: 34678088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.